Growth Hormone (gh) Or Derivative Patents (Class 514/11.3)
-
Publication number: 20120058190Abstract: A nutritional Composition for a subject, comprising prolactin identical or similar or analogous to prolactin found in a natural food source, and at least one protective layer, wherein release of said prolactin from the composition in said subject is the result of an environmental event.Type: ApplicationFiled: February 17, 2010Publication date: March 8, 2012Applicant: Technion-Research & Development Foundation LtdInventor: Naim Shehadeh
-
Publication number: 20120045430Abstract: Various nucleic acid-based matrixes are provided, comprising nucleic acid monomers as building blocks, as well as nucleic acids encoding proteins, so as to produce novel biomaterials. The nucleic acids are used to form dendrimers that are useful as supports, vectors, carriers or delivery vehicles for a variety of compounds in biomedical and biotechnological applications. In particular, the macromolecules may be used for the delivery of drugs, genetic material, imaging components or other functional molecule to which they can be conjugated. An additional feature of the macromolecules is their ability to be targeted for certain organs, tumors, or types of tissues. Methods of utilizing such biomaterials include delivery of functional molecules to cells.Type: ApplicationFiled: August 15, 2011Publication date: February 23, 2012Inventors: Dan Luo, Yougen Li
-
Publication number: 20120040886Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having proline substitution at position 34 and other substitution(s) as defined herein that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventor: Zheng Xin Dong
-
Publication number: 20120040885Abstract: The present invention relates to novel analogues of neuropeptide Y, pharmaceutical compositions containing the same, pharmaceutical formulations containing the same, and method of treating diseases or conditions mediated by neuropeptide Y-receptor binding. More particularly, the present invention relates to novel analogues of neuropeptide Y having at least one unnatural amino acid substitution, such as 4Hyp at position 34, that selectively bind to the neuropeptide Y1 receptor subtype compared to the neuropeptide Y2 receptor subtype.Type: ApplicationFiled: February 19, 2010Publication date: February 16, 2012Inventors: Zheng Xin Dong, Kevin Zhou, Daniel B. Deoliveira
-
Publication number: 20120035101Abstract: Use of a growth hormone protein and polynucleotides encoding same comprising an amino-terminal carboxy-terminal peptide (CTP) of chorionic gonadotrophin and two carboxy-terminal chorionic gonadotrophin CTPs attached to the growth hormone in methods of inducing growth or weight gain, method of increasing insulin-like growth factor (IGF-1) levels, and methods of reducing the dosing frequency of a growth hormone in a human subject are disclosed. Pharmaceutical compositions comprising the growth hormone and polynucleotides encoding the growth hormone of the invention and methods of using same are also disclosed.Type: ApplicationFiled: August 2, 2011Publication date: February 9, 2012Inventors: Fuad Fares, Udi Eyal Fima
-
Publication number: 20120027805Abstract: Described herein are methods and compositions for modulating the release and/or drug loading characteristics of encapsulated bioactive agents in polymer-based delivery systems via direct modification of the isoelectric point and/or net charge of the bioactive agent.Type: ApplicationFiled: August 28, 2009Publication date: February 2, 2012Applicant: Genzyme CorporationInventors: Kevin Burton, Torsten Woehr, Thomas R. Tice, Mimoun Ayoub
-
Publication number: 20120004167Abstract: The invention relates to substituted (2-aryloxyacetylamino)phenylpropionic acid derivatives, and to the physiologically acceptable salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, R8, R9 and A are each defined as specified, and the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.Type: ApplicationFiled: July 5, 2011Publication date: January 5, 2012Applicant: SANOFIInventors: Elisabeth DEFOSSA, Stefanie KEIL, Viktoria DIETRICH, Siegfried STENGELIN, Andreas HERLING, Guido HASCHKE, Thomas KLABUNDE
-
Publication number: 20120004166Abstract: The invention relates to aryloxyalkylene-substituted hydroxyphenylhexynoic acid derivatives, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14 and A are each defined as specified, and physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.Type: ApplicationFiled: July 5, 2011Publication date: January 5, 2012Applicant: SANOFIInventors: Stefanie KEIL, Elisabeth DEFOSSA, Viktoria DIETRICH, Siegfried STENGELIN, Andreas HERLING, Guido HASCHKE, Thomas KLABUNDE
-
Publication number: 20120004165Abstract: Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments The invention relates to heterocyclically substituted methoxyphenyl derivatives with an oxo group, and to physiologically compatible salts thereof. The invention relates to compounds of the formula I in which R1, R2, R3, R4, R10, X, n, B1, B2, B3 and B4 are each defined as specified, and to the physiologically compatible salts thereof. The compounds are suitable, for example, for treatment of diabetes.Type: ApplicationFiled: June 7, 2011Publication date: January 5, 2012Applicant: SANOFIInventors: Stefanie KEIL, Elisabeth DEFOSSA, Viktoria DIETRICH, Siegfried STENGELIN, Andreas HERLING, Guido HASCHKE, Thomas KLABUNDE
-
Publication number: 20110306548Abstract: The present invention relates to stable growth hormone (GH) compounds, which through the introduction of cysteine residues have disulphide bridges, which make the compounds resistant to proteolytic degradation.Type: ApplicationFiled: January 22, 2010Publication date: December 15, 2011Applicant: Novo Nordisk Health Care AGInventors: Ole Hvilsted Olsen, Jens Breinholt, Christine Bruun Schiødt, Helle Demuth, Leif Nørskov-Lauritsen, Peter Thygesen
-
Publication number: 20110293581Abstract: The present invention relates to a bone-regenerating composition containing angiogenin and to a bone-generating scaffold comprising the composition.Type: ApplicationFiled: February 2, 2009Publication date: December 1, 2011Inventors: Jun Lee, Dong-Hyeon Yoon, Dong-Hyeon Hwang
-
Publication number: 20110269681Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: ApplicationFiled: December 29, 2010Publication date: November 3, 2011Applicant: STEM CELL THERAPEUTICS INC.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20110263501Abstract: Novel growth hormone conjugates comprising a growth hormone compound (GH) and a growth hormone binding protein (GHBP) are disclosed. The invention also encompasses a novel derivatization method for producing stable, long-lasting conjugate (hGH-GHBP) by site specific conjugation. The novel GH-GHBP conjugates have an extended half-life in circulation that facilitates therapeutic use of the protein. The GH-GHBP conjugates exhibit pharmacological properties such as increased functional in vivo half-life, improved renal filtration, improved protease protection and albumin binding.Type: ApplicationFiled: September 9, 2009Publication date: October 27, 2011Applicant: Nono Nordisk Health Care AGInventor: Nils Langeland Johansen
-
Publication number: 20110257097Abstract: The invention provides a composition comprising (i) a somatotrophic hormone; (ii) a biodegradable polymer component; and (iii) a release modifier. A process for preparing, and the use of such a composition are also provided.Type: ApplicationFiled: July 10, 2009Publication date: October 20, 2011Inventors: Andrew Naylor, Andrew Lester Lewis, Lisbeth Illum
-
Publication number: 20110257098Abstract: The present invention relates to the use of genetic markers to identify the response to growth hormone treatment in Growth Hormone Deficiency (GHD) or Turner Syndrome (TS) patients as well as a method of treating GHD or TS patients and kits for genotyping.Type: ApplicationFiled: November 25, 2009Publication date: October 20, 2011Applicant: MERCK SERONO S.A.Inventors: Marianne Tuefferd, Jérôme Dauvillier, Arnaud Delaye, Sonia Schnieper-Samec
-
Publication number: 20110250169Abstract: The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby.Type: ApplicationFiled: May 13, 2011Publication date: October 13, 2011Inventor: George N. Cox, III
-
Publication number: 20110223233Abstract: A drug delivery device that includes a capsule for implantation into the body; the capsule further includes a reservoir for containing a substance such as a therapeutic agent, at least one port for allowing the substance to diffuse from or otherwise exit the reservoir, and a nanopore membrane in communication with the capsule at or near the exit port for controlling the rate of diffusion of the substance from the exit port. The device also includes an optional screen for providing structural stability to the nanopore membrane and for keeping the pores of the nanopore membrane clear. One embodiment of the drug delivery device includes an osmotic engine internal to the device for creating fluid flow through the device.Type: ApplicationFiled: April 29, 2011Publication date: September 15, 2011Applicant: Delpor, Inc.Inventors: FRANCIS J. MARTIN, ANTHONY A. BOIARSKI
-
Publication number: 20110208168Abstract: A liquid composition in an osmotic drug delivery system and a dosage form in an osmotic drug delivery system is disclosed comprising an amphiphilic molecule, a non-aqueous liquid solvent, and a pharmaceutically active agent.Type: ApplicationFiled: April 21, 2011Publication date: August 25, 2011Inventors: Rom Ezer Eliaz, Yuanpeng Zhang, Catherine Manya Rohloff, Eric William Weeks, Gunjan Junnarkar
-
Publication number: 20110206760Abstract: Provided are angiopoietin-derived peptides or homologs or derivatives thereof, pharmaceutical composition including them, a use thereof for therapy and for the manufacture of a medicament, a method of treating a wide range of conditions, disorders and diseases therewith, nucleotide sequences encoding them, antibodies directed to epitopes thereof and fusion proteins including them.Type: ApplicationFiled: July 20, 2009Publication date: August 25, 2011Applicant: COMPUGEN LTD.Inventors: Yossef Kliger, Itamar Borukhov, Ofer Levy, Zohar Tiran, Assaf Wool, Ehud Schreiber, Anat Amir, Zurit Levine, Amir Toporik
-
Patent number: 7998930Abstract: Provided are modified growth hormone polypeptides, nucleic acid molecules encoding modified growth hormone polypeptides and methods of generating modified growth hormone polypeptides. Also provided are methods of treatment using modified growth hormone polypeptides.Type: GrantFiled: November 3, 2005Date of Patent: August 16, 2011Assignee: HanAll BioPharma Co., Ltd.Inventors: Thierry Guyon, Gilles Borrelly, Lila Drittanti, Manuel Vega
-
Publication number: 20110195063Abstract: Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-? (TNF?) and are useful in vivo diagnosis and therapy of a number of TNF?-mediated pathologies and conditions, including ankylosing spondylitis, as well as polynucleotides coding for murine and chimeric antibodies, methods of producing the antibody, methods of use of the anti-TNF antibody, or fragment, region or derivative thereof, in immunoassays and immunotherapeutic approaches are provided.Type: ApplicationFiled: September 17, 2010Publication date: August 11, 2011Applicants: Centocor, Inc., New York UniversityInventors: Junming Le, Jan T. Vilcek, Peter E. Daddona, John Ghrayeb, David M. Knight, Scott A. Siegel, David J. Shealy
-
Publication number: 20110195020Abstract: The present invention concerns methods and compositions for making and using bioactive assemblies of defined compositions, which may have multiple functionalities and/or binding specificities. In particular embodiments, the bioactive assembly is formed using dock-and-lock (DNL) methodology, which takes advantage of the specific binding interaction between dimerization and docking domains (DDD) and anchoring domains (AD) to form the assembly. In various embodiments, one or more effectors may be attached to a DDD or AD sequence. Complementary AD or DDD sequences may be attached to an adaptor module that forms the core of the bioactive assembly, allowing formation of the assembly through the specific DDD/AD binding interactions. Such assemblies may be attached to a wide variety of effector moieties for treatment, detection and/or diagnosis of a disease, pathogen infection or other medical or veterinary condition.Type: ApplicationFiled: February 4, 2011Publication date: August 11, 2011Applicant: IBC PHARMACEUTICALS, INC.Inventors: Chien-Hsing Chang, David M. Goldenberg, William J. McBride, Edmund A. Rossi
-
Publication number: 20110172146Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in administration to animals.Type: ApplicationFiled: August 2, 2010Publication date: July 14, 2011Applicant: Amunix Operating, Inc.Inventors: VOLKER SCHELLENBERGER, Joshua Silverman, Willem P. Stemmer, Chia-Wei Wang, Nathan Geething
-
Publication number: 20110165145Abstract: Proteins that bind to IGF-II and/or IGF-IIE and methods of using such proteins are described. Also disclosed are new methods for treatment of cancer. Cancer is treated by administration of an IGF-II/IGF-IIE binding protein and an additional therapy such as a growth hormone/growth hormone releasing hormone pathway modulator or epidermal growth factor receptor inhibitor.Type: ApplicationFiled: May 8, 2009Publication date: July 7, 2011Inventors: Daniel T. Dransfield, Edward H. Cohen, Timothy Adams, Leah Cosgrove
-
Publication number: 20110165139Abstract: Provided are: an agent for promoting growth hormone-secretion, containing a milk-derived basic protein fraction as an active ingredient, with the promotion of growth hormone-secretion being mediated by the promotion of secretion of ghrelin having an effect for promoting growth hormone-secretion; and a method of promoting the secretion of ghrelin by using a milk-derived basic protein fraction. The agent for promoting growth hormone-secretion may be ingested on a daily basis and is highly safe even with its ingestion for a long period.Type: ApplicationFiled: March 10, 2011Publication date: July 7, 2011Applicant: SNOW BRAND MILK PRODUCTS CO., LTD.Inventors: Aiko ONO, Hiroaki MATSUYAMA, Yoshikazu MORITA, Atsushi SERIZAWA, Satoshi HIGURASHI
-
Publication number: 20110165262Abstract: Drug dependence or drug addiction is reduced by the administration to a subject of one or more of the following components: an antioxidant; vitamin B; a metal salt that provides metal ions, in vivo; insulin or a growth hormone; an antihistamine; and a herbal extract.Type: ApplicationFiled: January 26, 2006Publication date: July 7, 2011Inventors: Mishal Hamid Al-Sari, Rafida Mohammed Ahamed Al-Dabooni, Yousef Jameel
-
Publication number: 20110160129Abstract: Embodiments of the invention provide swallowable devices, preparations and methods for delivering drugs and other therapeutic agents within the GI tract. Many embodiments provide a swallowable device for delivering the agents. Particular embodiments provide a swallowable device such as a capsule for delivering drugs into the intestinal wall or other GI lumen. Embodiments also provide various drug preparations that are configured to be contained within the capsule, advanced from the capsule into the intestinal wall and degrade within the wall to release the drug to produce a therapeutic effect. The preparation can be coupled to an actuator having a first configuration where the preparation is contained in the capsule and a second configuration where the preparation is advanced out of the capsule into the intestinal wall. Embodiments of the invention are particularly useful for the delivery of drugs which are poorly absorbed, tolerated and/or degraded within the GI tract.Type: ApplicationFiled: December 23, 2010Publication date: June 30, 2011Applicant: InCube Labs, LLCInventor: Mir Imran
-
Publication number: 20110152190Abstract: A composition for administration of a beneficial agent, contains a solvent mixture including a hydrophobic solvent and a hydrophilic solvent; a bioerodible polymer; and a beneficial agent. The polymer and the beneficial agent are dissolved. The composition has a low viscosity, allowing for easy injection through standard hypodermic needles.Type: ApplicationFiled: June 24, 2010Publication date: June 23, 2011Inventors: Jeffrey L. CLELAND, Franklin Okumu
-
Publication number: 20110150837Abstract: The present invention relates to new amphiphilic polymers comprising hydrophobic groups and methionine groups. It also relates to compositions with a controlled release profile comprising such polymers, non-covalently combined with an active ingredient, in particular an active ingredient such as a peptide or a protein comprising in their sequence at least one amino acid which is sensitive to oxidation.Type: ApplicationFiled: December 23, 2010Publication date: June 23, 2011Applicant: Flamel TechnologiesInventors: You-Ping CHAN, Corine Vialas
-
Publication number: 20110142889Abstract: The invention provides a pharmaceutical composition for oral drug delivery comprising a solid dosage form containing an effective amount of a therapeutic agent, a permeation enhancer and a pharmaceutically acceptable excipient and a bioadhesive layer containing a bioadhesive polymer, and optionally comprising an impermeable or semi-permeable layer having an opening capable of directing a unidirectional release of the therapeutic agent and the permeation enhancer from the solid dosage form. Methods of making and using the present pharmaceutical composition are also provided.Type: ApplicationFiled: December 16, 2010Publication date: June 16, 2011Applicant: NOD Pharmaceuticals, Inc.Inventors: William W. Lee, Feng Lu, Min Yin
-
Publication number: 20110142800Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, methods for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.Type: ApplicationFiled: August 11, 2009Publication date: June 16, 2011Applicant: Oramed Ltd.Inventors: Miriam Kidron, Ehud Arbit
-
Publication number: 20110135661Abstract: The present invention relates to methods and compositions for the prevention and/or treatment of dry age-related macular degeneration by administering a CD 36-activator compound to a subject in need thereof; wherein the CD36 activator compound is the CD36 antibody FA6-152, or the growth hormone (GH)-releasing peptide family-derived compound EP80317 or the compound of Formula 1 [A-(Xaa)a-N(RA)—N(RB)—C(O)-(Xaa?)b-B]; and wherein the activator compound acts to maintain a healthy choroid and retinal oxygenation by enhanced COX2 expression.Type: ApplicationFiled: February 19, 2009Publication date: June 9, 2011Applicants: Universite De Montreal, Centre Hospitalier Universitaire Sainte-Justine, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Huy Ong, Sylvain Chemtob, Florian Sennlaub
-
Publication number: 20110129528Abstract: The present invention relates to a chitosan capsule in which a soluble active ingredient is encapsulated in a matrix containing chitosan and phytic acid; a cross-linking method and materials capable of being used in preparing the capsule; and pharmaceutical, food and cosmetic compositions comprising the capsule. The chitosan capsule according to the present invention is prepared via ionic gelation of chitosan as a biodegradable polymer with phytic acid capable of rapidly and effectively forming a cross-linking reaction with the chitosan polymer. The capsule of the present invention shows high encapsulation efficiency for a soluble active ingredient and protects the soluble active ingredient from being damaged in a digestive tract, resulting in improving an in vivo delivery efficiency of a physiologically active material.Type: ApplicationFiled: May 29, 2008Publication date: June 2, 2011Inventors: Ji Yong Park, Chan Min Jeong, Min Kyung Lee, Sung Won Choi, Young Hee Cho, Hoon Ok Jeong
-
Publication number: 20110130330Abstract: The present invention relates to compositions and methods for transdermal drug delivery comprising formulating a phosphatidylcholine carrier composition containing the drug and applying the composition to the skin.Type: ApplicationFiled: February 10, 2011Publication date: June 2, 2011Inventor: Nicholas V. Perricone
-
Publication number: 20110124558Abstract: The invention relates to the use of certain derivatives of D-mannopyranoside for controlling angiogenesis. These compounds have a pro-angiogenic activity, and can particularly be used for preparing a pharmaceutical composition for treating cardiovascular diseases or for treating muscular atrophy. The invention also relates to certain D-mannopyranoside derivatives, to a pharmaceutical or cosmetic composition containing said derivatives, and to the use of such a cosmetic composition for preventing and/or treating hair loss.Type: ApplicationFiled: May 5, 2009Publication date: May 26, 2011Applicant: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUEInventors: Jean-Louis Montero, Veronique Montero, Jean-Pierre Moles, Pascal De Santa Barbara, Bernard Jover
-
Publication number: 20110123577Abstract: A method of delivering a drug composition comprises providing a carrier having a phosphatidylcholine component and a drug entrapped therein, and applying the composition to the skin for transdermal delivery of the drug, wherein the composition is stable at room temperature.Type: ApplicationFiled: February 1, 2011Publication date: May 26, 2011Inventors: Nicholas V. Perricone, Chim Potini
-
Publication number: 20110123625Abstract: Provided are lipidic particles comprising phosphatidylcholine, phosphatidylinositol and cholesterol. Also provided are compositions comprising the lipidic particles and having associated therewith therapeutic agents such as peptides, polypeptides or proteins. In these compositions, the therapeutic agents have reduced immunogenicity and/or longer circulating time. These compositions can be used for therapeutic administration of the peptides, polypeptides and/or proteins.Type: ApplicationFiled: December 28, 2010Publication date: May 26, 2011Inventors: Sathy V. Balu-Iyer, Robert M. Straubinger, Razvan Miclea, Aaron Peng
-
Publication number: 20110097367Abstract: A method of making and using a monolithic alginate implant is described. The implant is formed by providing an uncrosslinked, highly pure and high molecular weight alginate solution and injecting the alginate solution into a patient at a predetermined site to form a gel body comprising the monolithic alginate implant. Spontaneous crosslinking of the monolithic alginate implant occurs at the predetermined site without the addition of an exogenous crosslinker. The implant may be used for treating medical conditions requiring support of sphincter musculature, reconstructive surgery, or cosmetic reconstruction, for the treatment of wrinkles on the hand, face, or décolleté, or for increasing volume, for example in the case of (HIV-induced) lipoatrophy of the breasts, and for the treatment of selected diseases, including gastrooesophageal reflux disease, urinary incontinence or vesicoureteral reflux disease.Type: ApplicationFiled: January 9, 2009Publication date: April 28, 2011Inventors: Christine Wallrapp, Herma Glöckner, Roland Reiner, Frank Thürmer
-
Publication number: 20110086003Abstract: The present invention relates to a stabilized solution comprising a hydrophobic protein, a method for the production thereof, and the stabilizing solution as a pharmaceutical, and the use thereof.Type: ApplicationFiled: October 7, 2008Publication date: April 14, 2011Applicant: STIFTUNG TIERARZTLICHE HOCHSCHULE HANNOVERInventors: Bernd Otto, Florian Battermann, Rudiger Kohl
-
Publication number: 20110077199Abstract: The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions.Type: ApplicationFiled: June 8, 2010Publication date: March 31, 2011Applicant: Amunix, Inc.Inventors: Volker Schellenberger, Joshua Silverman, Chia-wei Wang, Willem P. Stemmer, Nathan Geething
-
Publication number: 20110077195Abstract: An effective liquid preparation achieves high bioavailability (BA) of physiologically active peptides or proteins, including ghrelins, that are administered as drugs. Also provided is a method for improving the BA of physiologically active peptides or proteins, including ghrelins, that are subcutaneously injected in aqueous solutions. The liquid preparation contains: a physiologically active peptide or protein, such as ghrelins, as an active ingredient; an acid solution including one or a combination of two or more selected form the group consisting of acetic acid, lactic acid, phosphoric acid, glycine, citric acid, hydrochloric acid, propionic acid, butyric acid, benzoic acid and salts thereof; an alcohol; and a polar organic liquid including one or a combination of two or more selected from the group consisting of N-methyl-2-pyrrolidone, dimethylformamide, dimethylsulfoxide and methylparaben.Type: ApplicationFiled: August 2, 2010Publication date: March 31, 2011Applicants: ASUBIO PHARMA CO., LTD., KENJI KANGAWAInventors: Masaru Matsumoto, Masako Matsumoto, Takeshi Hanada, Naomi Wakabayashi
-
Publication number: 20110070188Abstract: Improved biodegradable and bioabsorbable BAB-block copolymers exhibiting reverse thermal gellation properties, and aqueous polymer compositions including the BAB-block copolymers, are provided. Methods of making the improved BAB-block copolymers and compositions including the same are also provided.Type: ApplicationFiled: September 20, 2010Publication date: March 24, 2011Applicant: Protherics Salt Lake City, Inc.Inventors: Kirk D. FOWERS, Ramesh C. RATHI, Ai-Zhi PIAO
-
Publication number: 20110052528Abstract: Embodiments of this invention provide novel peptidomimetics that contain a macrocycle. Such compounds are neuroprotective and have utility as therapeutic agents for treatment of diseases, injuries and other conditions characterised by neuronal degeneration and/or death. Compounds are also useful for manufacture of medicaments useful for treatment of such conditions.Type: ApplicationFiled: December 14, 2007Publication date: March 3, 2011Applicant: Neuren Pharmaceuticals LimitedInventors: Paul William Richard Harris, Margaret Anne Brimble
-
Publication number: 20110053848Abstract: The present invention relates to a prodrug or a pharmaceutically acceptable salt thereof comprising a drug linker conjugate D-L, wherein -D is an amine containing biologically active moiety; and -L is a non-biologically active linker moiety -L1 represented by formula (I), wherein the dashed line indicates the attachment to the amine of the biologically active moiety and wherein R1, R1a, R2, R2a, R3, R3a, X, X1, X2, X3 have the meaning as indicated in the description and the claims and wherein L1 is substituted with one to four groups L2-Z and optionally further substituted, provided that the hydrogen marked with the asterisk in formula (I) is not replaced by a substituent; wherein L2 is a single chemical bond or a spacer; and Z is a carrier group. The invention also relates to A-L, wherein A is a leaving group, pharmaceutical composition comprising said prodrugs and their use as medicaments.Type: ApplicationFiled: January 30, 2009Publication date: March 3, 2011Applicant: ASCENDIS PHARMA ASInventors: Felix Cleemann, Ulrich Hersel, Silvia Kaden, Harald Rau, Thomas Wegge
-
Publication number: 20110052531Abstract: Embodiments of this invention provide methods for therapeutic use of cyclic G-2-allylProline (cG-2-allylP) to treat peripheral neuropathies, including toxin-induced peripheral neuropathy and diabetic as well as manufacture of medicaments including tablets, capsules, and other orally active compositions containing cG-2-allylP, as well as injectable solutions that are useful for treatment of such conditions.Type: ApplicationFiled: September 27, 2010Publication date: March 3, 2011Inventors: Mike John Bickerdike, Margaret Anne Brimble, Ernest Stephen Sirimanne
-
Publication number: 20110046606Abstract: Catheter injectable depot compositions are provided that include a bioerodible, biocompatible polymer, a solvent having miscibility in water of less than or equal to 7 wt. % at 25° C., in an amount effective to plasticize the polymer and form a gel therewith, a thixotropic agent, and a beneficial agent. The solvent comprises an aromatic alcohol, an ester of an aromatic acid, an aromatic ketone, or mixtures thereof. The compositions are have substantially improved the shear thinning behavior and reduced injection force, rendering the compositions readily implanted beneath a patient's body surface by injection.Type: ApplicationFiled: October 18, 2010Publication date: February 24, 2011Inventors: Guohua Chen, Paul R. Houston, Lothar Kleiner, John J. Spaltro
-
Publication number: 20110038832Abstract: Provided herein are methods of treating macular degeneration, which comprises administering to a patient in need thereof a therapeutically effective amount of (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, or a pharmaceutically acceptable salt or solvate thereof.Type: ApplicationFiled: August 16, 2010Publication date: February 17, 2011Inventor: Jerome B. ZELDIS
-
Patent number: 7884072Abstract: The present invention provides a method of increasing neural stem cell numbers or neurogenesis by using prolactin. The method can be practiced in vivo to obtain more neural stem cells in situ, which can in turn produce more neurons or glial cells to compensate for lost or dysfunctional neural cells. The method can also be practiced in vitro to produce a large number of neural stem cells in culture. The cultured stem cells can be used, for example, for transplantation treatment of patients or animals suffering from neurodegenerative diseases or conditions. In addition, since neural stem cells are a source for olfactory neurons, the present invention also provides methods of increasing olfactory neurons and enhancing olfactory functions.Type: GrantFiled: March 19, 2008Date of Patent: February 8, 2011Assignee: Stem Cell Therapeutics Inc.Inventors: Tetsuro Shingo, Samuel Weiss
-
Publication number: 20110028388Abstract: The growth hormone with high biological activity modified by the double-stranded polyethylene glycol at a single site and the preparation method thereof are provided. The PEGylated growth hormone has a higher biological activity and a longer half-life than the unmodified growth hormone. The composition comprising the PEGylated growth hormone is useful in the treatment of the growth or development disorder such as growth hormone deficiency, Turner syndrome etc.Type: ApplicationFiled: April 3, 2008Publication date: February 3, 2011Inventor: Weidong ZHOU
-
Publication number: 20110020458Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.Type: ApplicationFiled: September 29, 2010Publication date: January 27, 2011Applicant: LG Life Sciences, Ltd., Inc.Inventors: Myung-Jin KIM, Sun-Jin Kim, Oh-Ryong Kwon